BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11830535)

  • 1. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
    Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
    Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Korngold R; Leighton C; Manser T
    Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
    Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
    Bhattacharyya S; Cowan MJ
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
    Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.